Skip to main content
66°
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
197.59
-0.62 (-0.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Biogen Idec
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Eli Lilly's Donanemab For Alzheimer's Hits FDA Speed Breaker, Biogen Stock Gains On Delayed Decision
March 08, 2024
The FDA's upcoming advisory committee meeting on Eli Lilly's Phase 3 donanemab trial for early symptomatic Alzheimer's. Understand safety and efficacy considerations, with a delay in expected FDA...
Via
Benzinga
Exposures
Product Safety
FDA Delays Decision On Eli Lilly's Alzheimer Drug
March 08, 2024
The FDA will hold an advisory panel for Lilly's Alzheimer drug donanemab.
Via
Investor's Business Daily
Exposures
Product Safety
Biogen's Spinraza For Muscle Movement Disorder Shows Improved Motor Function In Infants, Toddlers
March 06, 2024
Biogen's latest SMA research! Interim data from the RESPOND study reveals promising outcomes with SPINRAZA treatment. Learn about reduced NfL levels and the impact on infants and children with spinal...
Via
Benzinga
A Closer Look at 21 Analyst Recommendations For Biogen
March 05, 2024
Via
Benzinga
Biotechs on the Rise: 3 Stocks to Buy for a Shot of Profits
March 04, 2024
Given recent industry performance, the enthusiasm investors have for biotech stocks to buy is low. But these three companies seem promising.
Via
InvestorPlace
Biogen Unusual Options Activity
February 29, 2024
Via
Benzinga
Peering Into Biogen's Recent Short Interest
February 19, 2024
Via
Benzinga
Breaking Down Biogen: 8 Analysts Share Their Views
February 13, 2024
Via
Benzinga
1 Wall Street Analyst Thinks Biogen Stock Is Going to $311. Is It a Buy Around $223?
March 02, 2024
Getting its Alzheimer's medicine approved in the European Union could be big.
Via
The Motley Fool
Top Stocks Not Named Nvidia You Need To Know About In 2024: Here's What Investors Think About Them (Wall Street Vs. Reddit)
February 29, 2024
Nvidia Corp. is one of the leading top stocks with 60% gain in 2024, but other lesser-known names have outperformed.
Via
Benzinga
3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
February 22, 2024
With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year.
Via
InvestorPlace
From Zero to Hero: 7 Stock Losers That Could Turn Things Around in 2024
February 19, 2024
Although these companies suffered earlier, they could become stock turnarounds as investors recognize their potential.
Via
InvestorPlace
Biogen Slumps As Aduhelm Costs Squeeze Fourth-Quarter Profit
February 13, 2024
The company missed both sales and earnings expectations for the fourth quarter.
Via
Investor's Business Daily
Looking At Biogen's Recent Unusual Options Activity
February 12, 2024
Via
Benzinga
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness
February 15, 2024
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.
Via
InvestorPlace
Biogen Could Engage In $1B-$2B Deals To Fill Revenue Shortfall Gaps, Analyst Says
February 14, 2024
Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties.
Via
Benzinga
Citigroup To Rally Over 19%? Here Are 10 Top Analyst Forecasts For Wednesday
February 14, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Biogen (BIIB) Q4 2023 Earnings Call Transcript
February 13, 2024
BIIB earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Markets Tumble, VIX Up 8% On Hot Inflation Data, Dollar, Yields Jump As Traders Unwind Rate Cut Bets: What's Driving Markets Tuesday?
February 13, 2024
Wall Street witnessed one of the worst sessions since the beginning of the year, with widespread declines across the board as stocks were hit by the impact of a higher-than-expected inflation report.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Why Is Biogen Stock Trading Lower On Tuesday?
February 13, 2024
Biogen's Q4 2023 performance, with $2.39 billion in sales, adjusted EPS of $2.95, and updates on key drugs.
Via
Benzinga
Nasdaq, S&P 500 Set For Weaker Open As Traders Keep Eyes Peeled On Inflation Data: Analyst Flags Key CPI Report Item To Watch
February 13, 2024
Despite the Fed rhetoric about the inflation fight being still on, the central bank will likely cut rates this year, an analyst said.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
February 12, 2024
For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks.
Via
InvestorPlace
7 Biotech Stocks Fighting America’s Deadliest Diseases
February 08, 2024
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.
Via
InvestorPlace
Critical Insights From Biogen Analyst Ratings: What You Need To Know
January 24, 2024
Via
Benzinga
Earnings Scheduled For February 13, 2024
February 13, 2024
Companies Reporting Before The Bell • LCI Indus (NYSE:LCII) is likely to report quarterly earnings at $0.18 per share on revenue of $838.27 million.
Via
Benzinga
Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years
February 09, 2024
Via
Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
January 31, 2024
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval.
Via
Benzinga
Exposures
Product Safety
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
January 29, 2024
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and...
Via
Benzinga
AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
January 25, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
January 24, 2024
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
39
40
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.